1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,269 | 0,271 | 12.05. | |
| 0,256 | 0,270 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cosmos Health withdraws SEC registration statement | 4 | Investing.com | ||
| Di | Cosmos Health Inc.: Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 | 201 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that... ► Artikel lesen | |
| COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
| Mo | Cosmos Health Inc.: Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months | 279 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is... ► Artikel lesen | |
| Fr | Cosmos Health Inc.: Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed | 2.147 | ACCESS Newswire | 2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 reportEPS outlook upgraded: Zacks now expects Cosmos Health to... ► Artikel lesen | |
| 06.05. | Cosmos Health launches Fort18 men's wellness supplement in U.S. | 2 | Investing.com | ||
| 06.05. | Cosmos Health Inc: Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness | 362 | ACCESS Newswire | Science-based men's wellness: Fort18 is formulated with a proprietary five-ingredient botanical blend intended to support men's sexual staminaLarge and growing market: The U.S. sexual health supplement... ► Artikel lesen | |
| 30.04. | Cosmos Health projects Cur18 to generate $2.5M in U.S. revenue | 1 | Investing.com | ||
| 30.04. | Cosmos Health Inc.: Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months | 356 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that... ► Artikel lesen | |
| 21.04. | Cosmos Health Inc.: Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Valid | 938 | ACCESS Newswire | Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical... ► Artikel lesen | |
| 20.04. | Cosmos Health to begin Liv18 liver supplement production in April | 2 | Investing.com | ||
| 20.04. | Cosmos Health Inc: Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Pr | 311 | ACCESS Newswire | Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of scheduleProduction commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing... ► Artikel lesen | |
| 17.04. | Cosmos Health kündigt US-Marktstart für Curcumin-Präparat Cur18 an | 1 | Investing.com Deutsch | ||
| 17.04. | Cosmos Health plans Q2 U.S. launch of curcumin supplement | 1 | Investing.com | ||
| 17.04. | Cosmos Health Inc.: Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health | 522 | ACCESS Newswire | Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.Derived predominantly from turmeric (~98.5%), maintaining a composition... ► Artikel lesen | |
| 16.04. | Cosmos Health erweitert KI-Integration in operativen Prozessen | 3 | Investing.com Deutsch | ||
| 16.04. | Cosmos Health expands AI integration across operations | 2 | Investing.com | ||
| 16.04. | Cosmos Health Inc.: Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% | 459 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the... ► Artikel lesen | |
| 16.04. | Cosmos Health Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.04. | Cosmos Health Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 15.04. | Cosmos Holdings Non-GAAP EPS of -$0.12, revenue of $65.27M | 1 | Seeking Alpha |
1 2 3 4 5 Weiter >>
86 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 39,655 | -0,51 % | BÖRSE AKTUELL: Axios-Meldungen treiben die europäischen Märkte an; Novo Nordisk als Star des Tages | ||
| PFIZER | 22,040 | +0,55 % | Ihre wichtigsten Termine: Spannende Updates von: Pfizer, PayPal, American Express, Cummins, SAP & Biontech | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:00... ► Artikel lesen | |
| NOVARTIS | 126,02 | +2,31 % | Pharmasektor wieder interessant? Eli Lilly, Novartis, Vidac Pharma | Der Pharmasektor ist von stetigen Höhen und Tiefen gekennzeichnet und während es bei dem einen Unternehmen nicht besser laufen kann, werden bei dem nächsten Unternehmen nur leichte Verfehlungen der... ► Artikel lesen | |
| AURORA CANNABIS | 2,882 | -1,03 % | AURORA CANNABIS INC: Ruhe vor dem nächsten Impuls | ||
| SANOFI | 73,47 | +0,89 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| GSK | 21,790 | +2,06 % | BERNSTEIN RESEARCH stuft GSK auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für GSK von 2750 auf 2630 Pence gesenkt, die Einstufung aber auf "Outperform" belassen. Justin Smith legte in einer... ► Artikel lesen | |
| CANOPY GROWTH | 0,940 | -2,95 % | CANOPY GROWTH CORPORATION: Struktur vor Impuls | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| ELI LILLY | 843,00 | +2,65 % | Lilly reports weight maintenance data for Foundayo, Zepbound | ||
| MERCK & CO | 95,90 | +1,43 % | BioInvent International: BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA in Advanced CTCL | 40% objective response rate (ORR) as single agent in heavily pre-treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL)Durable responses observed, including a complete response lasting over... ► Artikel lesen | |
| TILRAY BRANDS | 4,610 | -1,81 % | Tilray Brands, Inc.: BrewDog Announces Partnership with Underbelly as Official Beer Supplier of Underbelly at the Edinburgh Fringe | The 12-month Deal Also Includes Seasonal Festival Support in London and a Permanent Live Venue
ELLON, Scotland, May 05, 2026 (GLOBE NEWSWIRE) -- Scottish Brewer, BrewDog, by?Tilray Brands, Inc.?(NASDAQ:... ► Artikel lesen | |
| TEVA | 30,400 | -0,33 % | Teva Pharm Q1 2026: Innovatives Portfolio wächst um 41 %, Emalex-Übernahme angekündigt | ||
| VERTEX PHARMACEUTICALS | 381,60 | +3,26 % | Vertex Pharmaceuticals Incorporated: Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany | -The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today... ► Artikel lesen | |
| INNOCAN PHARMA | 3,220 | 0,00 % | Breaking News: Schmerzfrei ohne Nebenwirkung?! - Fachblatt berichtet! | ||
| ABBOTT LABORATORIES | 71,94 | +2,62 % | GLP-1 Hydration Products Market Outlook 2036 with Key Contributions from Smoothie King, Liquid I.V., Electrolit, Abbott, Nestlé Health Science, and ADM | Future Market Insights | NEWARK, Del., May 5, 2026 /PRNewswire/ -- According to the latest market analysis by Future Market Insights (FMI), the global GLP-1 hydration products market is entering a rapid expansion... ► Artikel lesen |
COSMOS HEALTH INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,268 Euro und damit +1,82 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COSMOS HEALTH INC finden Sie auf Wallstreet Online.